KUALA LUMPUR: Universiti Teknologi MARA (UiTM) could potentially lose some RM51.08mil following delays in seeking compensation from 239 scholarship holders, who breached their contracts.

AC220 is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc., and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.